News about Global Pharma

GemPharmatech Opens New San Diego Biotech Hub Facility

GemPharmatech has opened its newly expanded US headquarters in San Diego, featuring a state-of-the-art vivarium and lab space to enhance preclinical research support for the North American biomedical community.

Global Pharma | 28/04/2025 | By Manvi |  252

Ormco Launches Spark Retainers and BiteSync Class II Corrector in US at AAO 2025

Developed for doctors and patients, Spark Retainers bring a new level of comfort, durability, and clinical flexibility to orthodontic retainers whether treating with Spark™ Clear Aligners, Ormco™ Digital Bonding, or fixed brackets.

Global Pharma | 28/04/2025 | By Manvi |  726

SS Innovations Lists on NASDAQ, Marking Global Milestone for Indian Surgical Robotics

SS Innovations International has made remarkable progress with its clinically validated and patented SSI Mantra Surgical Robotic System, which has been installed in 80 hospitals across 75 locations in India, as well as expanding its footprint in countries including Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka, and Ukraine.

Global Pharma | 28/04/2025 | By Manvi |  420

Life Molecular Imaging's Neuraceq Now Available at PharmaLogic's Salt Lake City Facility

Life Molecular Imaging and PharmaLogic have expanded their strategic partnership to produce and distribute Neuraceq from PharmaLogic’s Salt Lake City facility, with commercial doses available from April 23, 2025.

Global Pharma | 25/04/2025 | By Manvi |  195

CIRCA Scientific's PeriCross Access Kit Receives FDA 510(k) Clearance

CIRCA Scientific announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the PeriCross™ Epicardial Access Kit (formerly Rook®), a purpose-built solution designed to enable controlled and efficient access to the pericardial space via a subxiphoid approach.

Global Pharma | 25/04/2025 | By Manvi |  341

Boston Scientific Reports Positive 12-Month FARAPULSE Trial Results

Persistent AF, which accounts for approximately 25 percent 1 of all AF cases, is an abnormal, rapid heartbeat that lasts for at least seven days in a row and can lead to complications such as blood clots, stroke and heart failure.

Global Pharma | 25/04/2025 | By Manvi |  464

Lupin Gets USFDA Approval for Tolvaptan Tablets

Lupin has received US FDA approval for its generic Tolvaptan Tablets, becoming the exclusive first-to-file applicant with 180-day marketing exclusivity in the US. The tablet is used for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It will be manufactured in the company’s Nagpur facility.

Global Pharma | 25/04/2025 | By Manvi |  540

Landmark BioVentures and G.CLIPS Biotech Form Strategic Alliance to Bridge Gaps in Drug Target Engagement

Landmark BioVentures and G.CLIPS Biotech have announced a strategic alliance to strengthen early-stage drug development by addressing critical gaps in target engagement and physiopathology, enhancing efficiency and reducing risk across the development pipeline.

Global Pharma | 24/04/2025 | By Manvi |  296

CGBIO's NOVOSIS PUTTY Wins FDA IDE Approval for US Spinal Trial

This milestone marks NOVOSIS PUTTY as the first Korean-developed bio-combined medical device to reach this stage in the US, signifying a significant step toward Premarket Approval (PMA) and subsequent commercialization.

Global Pharma | 24/04/2025 | By Manvi |  222

SimonMed Partners with Lunit to Advance AI-Powered Breast Cancer Detection

SimonMed has selected Lunit INSIGHT DBT™, in combination with Volpara Analytics™, as the most advanced AI solution for breast cancer screening after an extensive evaluation of technologies on the market.

Global Pharma | 24/04/2025 | By Manvi |  193